The AI in Business Podcast Scaling AI for Clinical Trials - with Damion Nero of Takeda
9 snips
May 7, 2025 Damion Nero, Head of Data Science at Takeda Pharmaceuticals, shares his expertise in applying AI and machine learning to drug development. He discusses how AI is revolutionizing clinical trials by streamlining tasks and enhancing patient engagement. Topics include the transformative potential of decentralized models and the integration of diverse data sources. Damion also highlights the ongoing challenges of trust and data integrity in healthcare, as well as the promise of future advancements in supply chain efficiency.
AI Snips
Chapters
Transcript
Episode notes
AI Enables Decentralized Trials
- AI is critical in decentralized clinical trials enabling remote patient data collection and interaction.
- Technologies like chatbots enhance efficiency by reducing healthcare professionals' workload in routine patient checkups.
AI's Strengths and Limits in Drug Trials
- AI impacts drug development more in common diseases with large patient data rather than rare diseases.
- Computer vision AI objectively assesses tumor imaging much faster and more accurately than humans.
Challenges of Fragmented Patient Data
- Fragmented and sporadic historical patient data remains a major challenge in clinical trials.
- Despite distrust in pharma, patients ultimately seek care, enabling partial data capture for analysis.